Enanta Pharmaceuticals Inc
(NAS:ENTA)
$
11.26
0.15 (1.35%)
Market Cap: 238.58 Mil
Enterprise Value: 55.89 Mil
PE Ratio: 0
PB Ratio: 1.60
GF Score: 61/100 Enanta Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2023 / 06:05PM GMT
Release Date Price:
$25.5
(+3.49%)
Brian Abrahams
RBC Capital Markets - Analyst
Let's get started. Hi, again, everyone. I'm Brian Abrahams, one of the senior biotech analysts at RBC Capital Markets. Our next presenting company is Enanta Pharmaceuticals, represented by their President and CEO, Jay Luly, and their SVP of New Product Strategy and Development, Tara Kieffer. Jay and Tara, thanks so much for joining us.
Tara Kieffer
Enanta Pharmaceuticals Inc. - SVP, New Product Strategy and Development
Thanks for inviting us.
Questions & Answers
Brian Abrahams
RBC Capital Markets - Analyst
So just to kick things off, you guys recently presented some data for your asset 235 in COVID, actually just over a week or so ago. Can you maybe just start by walking us through the key findings from that data? What were the most notable signals of efficacy that you observed there?
Jay Luly
Enanta Pharmaceuticals Inc. - President, CEO & Director
So before we begin, I want to remind you, I will be making
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot